Safety and Local Tolerability of Prevenar in Indian Children


Last updated date


Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center


By email


[email protected]

Call Now

Eligibility Criteria
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Infections
Females and Males
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-24 weeks


Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center


[email protected]


Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pneumococcal InfectionsStudy Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India NCT00452790
  1. Sector-12, Chandigarh
  2. Sector-32 B, Chandigarh
  3. Bangalore, Karnataka
  4. Bangalore, Karnataka
  5. Mumbai, Maharashtra
  6. Pune, Maharashtra
  7. Pune, Maharashtra
  8. Pune, Maharashtra
  9. Rajinder Nagar, New Delhi
  10. Ludhiana, Punjab
  11. Chennai, Tamil Nadu
  12. Vellore, Tamil Nadu
42 Days+
Pneumococcal InfectionsStudy Investigating Administration of Prevenar for Post-Marketing Surveillance NCT00195390
  1. Seoul,
6 Weeks+
Pneumococcal InfectionsStudy to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants NCT03550313
  1. Miami, Florida
  2. Houston, Texas
  3. Saint George, Utah
  4. Harrisburg, Arkansas
  5. Anaheim, California
  6. Downey, California
  7. Huntington Beach, California
  8. Madera, California
  9. Ontario, California
  10. Paramount, California
  11. San Diego, California
  12. Boynton Beach, Florida
  13. DeLand, Florida
  14. Homestead, Florida
  15. Miami Lakes, Florida
  16. Miami, Florida
  17. Miami, Florida
  18. Columbus, Georgia
  19. Park Ridge, Illinois
  20. Mishawaka, Indiana
  21. Louisville, Kentucky
  22. Nicholasville, Kentucky
  23. Baton Rouge, Louisiana
  24. Metairie, Louisiana
  25. Shreveport, Louisiana
  26. Shreveport, Louisiana
  27. Silver Spring, Maryland
  28. Boston, Massachusetts
  29. Kansas City, Missouri
  30. Omaha, Nebraska
  31. East Syracuse, New York
  32. Liverpool, New York
  33. Boone, North Carolina
  34. Winston-Salem, North Carolina
  35. Winston-Salem, North Carolina
  36. Dayton, Ohio
  37. Erie, Pennsylvania
  38. Charleston, South Carolina
  39. Greenville, South Carolina
  40. Sioux Falls, South Dakota
  41. Sioux Falls, South Dakota
  42. Sioux Falls, South Dakota
  43. Sioux Falls, South Dakota
  44. Sioux Falls, South Dakota
  45. Sioux Falls, South Dakota
  46. Kingsport, Tennessee
  47. Houston, Texas
  48. Houston, Texas
  49. Keller, Texas
  50. San Antonio, Texas
  51. Spring, Texas
  52. Spokane, Washington
42 Days+
Pneumococcal InfectionsTrial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants NCT03512288
  1. Fayetteville, Arkansas
  2. Downey, California
  3. Huntington Beach, California
  4. Oakland, California
  5. Ontario, California
  6. Sacramento, California
  7. San Jose, California
  8. Santa Clara, California
  9. Haughton, Louisiana
  10. Metairie, Louisiana
  11. Shreveport, Louisiana
  12. Shreveport, Louisiana
  13. Omaha, Nebraska
  14. East Syracuse, New York
  15. Boone, North Carolina
  16. Raleigh, North Carolina
  17. Cincinnati, Ohio
  18. Cincinnati, Ohio
  19. Cincinnati, Ohio
  20. Cincinnati, Ohio
  21. Cincinnati, Ohio
  22. Dayton, Ohio
  23. South Euclid, Ohio
  24. Tulsa, Oklahoma
  25. Erie, Pennsylvania
  26. Hermitage, Pennsylvania
  27. Philadelphia, Pennsylvania
  28. Charleston, South Carolina
  29. Charleston, South Carolina
  30. North Charleston, South Carolina
  31. Galveston, Texas
  32. San Antonio, Texas
  33. Layton, Utah
  34. Murray, Utah
  35. Roy, Utah
  36. South Jordan, Utah
  37. Syracuse, Utah
  38. Charlottesville, Virginia
  39. Charlottesville, Virginia
42 Days+
Advanced Information
Descriptive Information
Brief Title Safety and Local Tolerability of Prevenar in Indian Children
Official Title A Postmarketing Surveillance Study Evaluating the Safety and Local Tolerance of PREVENAR in Indian Children
Brief Summary

This postmarketing surveillance study will evaluate the safety profile of Prevenar in Indian children.

Prevenar is indicated for active immunization of infants and children from 6 weeks of age through 9 years of age against invasive disease (including meningitis, bacteraemic pneumonia, bacteraemia, sepsis) caused by Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.

Prevenar has been marketed in India since June 2006. The Board of Health in India has given restricted permission to import and market Prevenar. The present study is a post-approval regulatory commitment to the Board of Health in India.

This is an observational study and the protocol for the study has been approved by the Board of Health.

Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Not Provided
Study Population Not Provided
Condition Pneumococcal Infections
Intervention Biological: pneumococcal conjugate vaccine
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status Completed
 (submitted: June 19, 2007)
Original Enrollment Same as current
Actual Study Completion Date January 2007
Actual Primary Completion Date January 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria


Subjects must meet at least one of the following conditions to be eligible for inclusion in the study:

For Primary Immunization Schedule:

  • Healthy male or female subjects 6 weeks + 5 days of age with no previous PREVENAR vaccination
  • For Catch-up Immunization Schedule:
  • Healthy male or female subjects 12-23 months of age

EXCLUSION CRITERIA Subjects with any of the following conditions or characteristics will be excluded from the study.

  • A known or suspected history of Streptococcus pneumoniae disease.
  • A previous anaphylactic or other severe vaccine-associated adverse event.
  • A known or suspected impairment of immune system (including HIV infection), or recipient of immunosuppressive agents.
  • A major congenital, developmental or serious chronic disorder.
  • A confirmed or suspected underlying evolving neurological disorder or history of seizures.
  • A history of thrombocytopenia or any coagulation disorder.
  • Any acute illness at the time of vaccine administration
Sexes Eligible for Study:All
Ages 6 Weeks to 24 Months   (Child)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Not Provided
Removed Location Countries  
Administrative Information
NCT Number NCT00488800
Other Study ID Numbers 0887X-102324
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date December 2007